Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts

International Journal of Cancer

Volumn 129, Issue 3, 2011, Pages 742-750

  Bruheim, Skjalg ^a,c   Kristian, Alexandr ^a   Uenaka, Toshimitsu ^b   Suo, Zhenhe ^a,c   Tsuruoka, Akihiko ^b   Nesland, Jahn M ^a,c   Fodstad, Øystein ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b EISAI CO LTD   (Japan)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

antiangiogenic therapy; human sarcoma xenografts; receptor tyrosine kinase inhibitors

Indexed keywords

CD31 ANTIGEN; CISPLATIN; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IFOSFAMIDE; LENVATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PARAMETERS; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME INHIBITION; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEIOMYOSARCOMA; LETHALITY; LIPOSARCOMA; MICROVASCULATURE DENSITY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINOLINES; SARCOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958037590     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25922     Document Type: Article

References (26)

1. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA,. Opportunities for improving the therapeutic ratio for patients with sarcoma. The Lancet Oncol 2007; 8: 513-24. (Pubitemid 46823060)
2. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9. (Pubitemid 46621810)
3. Folkman J, Watson K, Ingber D, Hanahan D,. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61. (Pubitemid 19115892)
4. Hanahan D, Folkman J,. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64. (Pubitemid 26272076)
5. Balasubramanian L, Evens AM,. Targeting angiogenesis for the treatment of sarcoma. Curr Opin in Oncol 2006; 18: 354-9. (Pubitemid 44297246)
6. Ferrara N,. VEGF and the quest for tumour angiogenesis factors. Nat Rev 2002; 2: 795-803. (Pubitemid 37328914)
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New Engl J Med 2004; 350: 2335-42. (Pubitemid 38702844)
8. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M,. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14: 5459-65.
9. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M,. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008; 122: 664-71. (Pubitemid 350308963)
10. Weidner N,. Chapter 14. Measuring intratumoral microvessel density. Methods in Enzymol 2008; 444: 305-23.
11. Wunder JS, Eppert K, Burrow SR, Gokgoz N, Bell RS, Andrulis IL,. Co-amplification and overexpression of CDK4, SAS and MDM2 °Ccurs frequently in human parosteal osteosarcomas. Oncogene 1999; 18: 783-8. (Pubitemid 29080336)
12. Peterson JK, Houghton PJ,. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004; 40: 837-44. (Pubitemid 38519762)
13. D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H, Maki RG,. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23: 7135-42.
14. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-40.
15. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-32.
16. Rini BI,. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007; 13: 1098-106. (Pubitemid 46424048)
17. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB,. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-44. (Pubitemid 46733080)
18. Casanovas O, Hicklin DJ, Bergers G, Hanahan D,. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309. (Pubitemid 41443415)
19. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95. (Pubitemid 46075199)
20. D'Amore PA,. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. The Am J Pathol 2007; 171: 14-8. (Pubitemid 47339222)
21. Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE, Ellis LM,. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 2001; 15: 1239-41.
22. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E,. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. The J Clin Invest 1999; 103: 159-65. (Pubitemid 29053133)
23. Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergun S, Schadendorf D,. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. The J Exp Med 207: 491-503.
24. Jain RK,. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62. (Pubitemid 40093472)
25. Jain RK, Tong RT, Munn LL,. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007; 67: 2729-35. (Pubitemid 46548961)
26. Tredan O, Galmarini CM, Patel K, Tannock IF,. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-54.